ID

36993

Description

Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT02353143

Link

https://clinicaltrials.gov/show/NCT02353143

Keywords

Versions (1)
  1. 6/26/19 6/26/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

June 26, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Recurrent Adult Acute Myeloid Leukemia NCT02353143

English

Eligibility Recurrent Adult Acute Myeloid Leukemia NCT02353143

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
male or female patients aged ≥ 18 years.
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
documented definitive diagnosis of aml (according to who criteria, 2008) that is relapsed/refractory to standard treatment, for which no standard therapy is available or the patient refuses standard therapy.
Description

Leukemia, Myelocytic, Acute | Standard of Care AML recurrent | Standard of Care Refractory AML | Standard of Care Unavailable | Standard of Care Refused

Data type

boolean

Alias
UMLS CUI [1]
C0023467
UMLS CUI [2,1]
C2936643
UMLS CUI [2,2]
C1142169
UMLS CUI [3,1]
C2936643
UMLS CUI [3,2]
C4528668
UMLS CUI [4,1]
C2936643
UMLS CUI [4,2]
C0686905
UMLS CUI [5,1]
C2936643
UMLS CUI [5,2]
C1705116
wbc count ≤ 10 x 109/l at visit 1 (day 1); hydroyxurea is allowed to lower wbc count up to one day prior the first study drug administration.
Description

White Blood Cell Count procedure | Hydroxyurea allowed | Hydroxyurea Lowering White Blood Cell Count

Data type

boolean

Alias
UMLS CUI [1]
C0023508
UMLS CUI [2,1]
C0020402
UMLS CUI [2,2]
C0683607
UMLS CUI [3,1]
C0020402
UMLS CUI [3,2]
C2003888
UMLS CUI [3,3]
C0023508
eastern cooperative oncology group (ecog) performance status of 0 to 2 at visit 1 (day 1).
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
life expectancy of at least 2 months.
Description

Life Expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
adequate renal and hepatic laboratory assessments: aspartate aminotransferase (ast), alanine aminotransferase (alt) and alkaline phosphatase (alp) ≤3.0 × uln, unless considered due to leukemic organ involvement, total bilirubin ≤2.0 × uln, serum creatinine ≤2.0 × uln.
Description

Laboratory test renal | Laboratory test hepatic | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Alkaline phosphatase measurement | Exception Organ Involvement with Leukemia | Serum total bilirubin measurement | Creatinine measurement, serum

Data type

boolean

Alias
UMLS CUI [1,1]
C0022885
UMLS CUI [1,2]
C0022646
UMLS CUI [2,1]
C0022885
UMLS CUI [2,2]
C0205054
UMLS CUI [3]
C0201899
UMLS CUI [4]
C0201836
UMLS CUI [5]
C0201850
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C0178784
UMLS CUI [6,3]
C1314939
UMLS CUI [6,4]
C0023418
UMLS CUI [7]
C1278039
UMLS CUI [8]
C0201976
able to give written informed consent before any study related procedure
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
acute promyelocytic leukaemia (french-american-british m3 classification).
Description

Acute Promyelocytic Leukemia French-American-British Classification

Data type

boolean

Alias
UMLS CUI [1,1]
C0023487
UMLS CUI [1,2]
C2984084
active central nervous system involvement.
Description

Central Nervous System Involvement

Data type

boolean

Alias
UMLS CUI [1]
C4050309
haematopoietic stem cell transplantation (hsct) performed within 3 months prior to screening visit.
Description

Hemopoietic stem cell transplant

Data type

boolean

Alias
UMLS CUI [1]
C0472699
active infection requiring intravenous antibiotics.
Description

Communicable Disease Requirement Antibiotics Intravenous

Data type

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C1514873
UMLS CUI [1,3]
C0003232
UMLS CUI [1,4]
C1522726
life-threatening illnesses other than aml, uncontrolled medical conditions or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety or interfere with the patient's ability to comply with the study activities.
Description

Life threatening illness compromises Patient safety | Life threatening illness Interferes with Protocol Compliance | Exception AML | Medical condition Uncontrolled | Organ system Dysfunction

Data type

boolean

Alias
UMLS CUI [1,1]
C3846017
UMLS CUI [1,2]
C2945640
UMLS CUI [1,3]
C1113679
UMLS CUI [2,1]
C3846017
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C0525058
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0023467
UMLS CUI [4,1]
C3843040
UMLS CUI [4,2]
C0205318
UMLS CUI [5,1]
C0682591
UMLS CUI [5,2]
C3887504
anti-tumour therapy within 14 days of study visit 1 (day 1, excluding hydroxyurea).
Description

Cancer treatment | Exception Hydroxyurea

Data type

boolean

Alias
UMLS CUI [1]
C0920425
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0020402
prior participation in an investigational study (procedure or device) within 21 days of study visit 1 (day 1).
Description

Study Subject Participation Status | Procedure Investigational | Investigational Medical Device

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2,1]
C0184661
UMLS CUI [2,2]
C1517586
UMLS CUI [3]
C2346570
radiotherapy within 28 days prior to study visit 1 (day 1) or scheduled along the study conduct.
Description

Therapeutic radiology procedure | Therapeutic radiology procedure Scheduled

Data type

boolean

Alias
UMLS CUI [1]
C1522449
UMLS CUI [2,1]
C1522449
UMLS CUI [2,2]
C0205539
known history of human immunodeficiency virus (hiv) or active infection with hepatitis c virus (hcv) or hepatitis b virus (hbv).
Description

HIV Infection | Hepatitis C | Hepatitis B

Data type

boolean

Alias
UMLS CUI [1]
C0019693
UMLS CUI [2]
C0019196
UMLS CUI [3]
C0019163
other active malignancies. history of malignancy in the last 12 months (except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast or non-melanoma skin cancer).
Description

Cancer Other | Exception Basal cell carcinoma | Exception Squamous cell carcinoma of skin | Exception Carcinoma in situ of uterine cervix | Exception Breast Carcinoma | Exception Skin carcinoma

Data type

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0007117
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0553723
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0851140
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0678222
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C0699893
Back to the top of the page

Similar models

Eligibility Recurrent Adult Acute Myeloid Leukemia NCT02353143

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
male or female patients aged ≥ 18 years.
boolean
C0001779 (UMLS CUI [1])
Leukemia, Myelocytic, Acute | Standard of Care AML recurrent | Standard of Care Refractory AML | Standard of Care Unavailable | Standard of Care Refused
Item
documented definitive diagnosis of aml (according to who criteria, 2008) that is relapsed/refractory to standard treatment, for which no standard therapy is available or the patient refuses standard therapy.
boolean
C0023467 (UMLS CUI [1])
C2936643 (UMLS CUI [2,1])
C1142169 (UMLS CUI [2,2])
C2936643 (UMLS CUI [3,1])
C4528668 (UMLS CUI [3,2])
C2936643 (UMLS CUI [4,1])
C0686905 (UMLS CUI [4,2])
C2936643 (UMLS CUI [5,1])
C1705116 (UMLS CUI [5,2])
White Blood Cell Count procedure | Hydroxyurea allowed | Hydroxyurea Lowering White Blood Cell Count
Item
wbc count ≤ 10 x 109/l at visit 1 (day 1); hydroyxurea is allowed to lower wbc count up to one day prior the first study drug administration.
boolean
C0023508 (UMLS CUI [1])
C0020402 (UMLS CUI [2,1])
C0683607 (UMLS CUI [2,2])
C0020402 (UMLS CUI [3,1])
C2003888 (UMLS CUI [3,2])
C0023508 (UMLS CUI [3,3])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of 0 to 2 at visit 1 (day 1).
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
life expectancy of at least 2 months.
boolean
C0023671 (UMLS CUI [1])
Laboratory test renal | Laboratory test hepatic | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Alkaline phosphatase measurement | Exception Organ Involvement with Leukemia | Serum total bilirubin measurement | Creatinine measurement, serum
Item
adequate renal and hepatic laboratory assessments: aspartate aminotransferase (ast), alanine aminotransferase (alt) and alkaline phosphatase (alp) ≤3.0 × uln, unless considered due to leukemic organ involvement, total bilirubin ≤2.0 × uln, serum creatinine ≤2.0 × uln.
boolean
C0022885 (UMLS CUI [1,1])
C0022646 (UMLS CUI [1,2])
C0022885 (UMLS CUI [2,1])
C0205054 (UMLS CUI [2,2])
C0201899 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
C0201850 (UMLS CUI [5])
C1705847 (UMLS CUI [6,1])
C0178784 (UMLS CUI [6,2])
C1314939 (UMLS CUI [6,3])
C0023418 (UMLS CUI [6,4])
C1278039 (UMLS CUI [7])
C0201976 (UMLS CUI [8])
Informed Consent
Item
able to give written informed consent before any study related procedure
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Acute Promyelocytic Leukemia French-American-British Classification
Item
acute promyelocytic leukaemia (french-american-british m3 classification).
boolean
C0023487 (UMLS CUI [1,1])
C2984084 (UMLS CUI [1,2])
Central Nervous System Involvement
Item
active central nervous system involvement.
boolean
C4050309 (UMLS CUI [1])
Hemopoietic stem cell transplant
Item
haematopoietic stem cell transplantation (hsct) performed within 3 months prior to screening visit.
boolean
C0472699 (UMLS CUI [1])
Communicable Disease Requirement Antibiotics Intravenous
Item
active infection requiring intravenous antibiotics.
boolean
C0009450 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0003232 (UMLS CUI [1,3])
C1522726 (UMLS CUI [1,4])
Life threatening illness compromises Patient safety | Life threatening illness Interferes with Protocol Compliance | Exception AML | Medical condition Uncontrolled | Organ system Dysfunction
Item
life-threatening illnesses other than aml, uncontrolled medical conditions or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety or interfere with the patient's ability to comply with the study activities.
boolean
C3846017 (UMLS CUI [1,1])
C2945640 (UMLS CUI [1,2])
C1113679 (UMLS CUI [1,3])
C3846017 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0525058 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0023467 (UMLS CUI [3,2])
C3843040 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
C0682591 (UMLS CUI [5,1])
C3887504 (UMLS CUI [5,2])
Cancer treatment | Exception Hydroxyurea
Item
anti-tumour therapy within 14 days of study visit 1 (day 1, excluding hydroxyurea).
boolean
C0920425 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0020402 (UMLS CUI [2,2])
Study Subject Participation Status | Procedure Investigational | Investigational Medical Device
Item
prior participation in an investigational study (procedure or device) within 21 days of study visit 1 (day 1).
boolean
C2348568 (UMLS CUI [1])
C0184661 (UMLS CUI [2,1])
C1517586 (UMLS CUI [2,2])
C2346570 (UMLS CUI [3])
Therapeutic radiology procedure | Therapeutic radiology procedure Scheduled
Item
radiotherapy within 28 days prior to study visit 1 (day 1) or scheduled along the study conduct.
boolean
C1522449 (UMLS CUI [1])
C1522449 (UMLS CUI [2,1])
C0205539 (UMLS CUI [2,2])
HIV Infection | Hepatitis C | Hepatitis B
Item
known history of human immunodeficiency virus (hiv) or active infection with hepatitis c virus (hcv) or hepatitis b virus (hbv).
boolean
C0019693 (UMLS CUI [1])
C0019196 (UMLS CUI [2])
C0019163 (UMLS CUI [3])
Cancer Other | Exception Basal cell carcinoma | Exception Squamous cell carcinoma of skin | Exception Carcinoma in situ of uterine cervix | Exception Breast Carcinoma | Exception Skin carcinoma
Item
other active malignancies. history of malignancy in the last 12 months (except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast or non-melanoma skin cancer).
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0553723 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0851140 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0678222 (UMLS CUI [5,2])
C1705847 (UMLS CUI [6,1])
C0699893 (UMLS CUI [6,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial